Video Library

Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.

Beth Faiman PhD, MSN, provides expert insight on tactics for managing oral toxicities associated with talquetamab treatment among patients with relapsed/refractory multiple myeloma.

Caroline Schinke, MD, Myeloma Center at the University of Arkansas, speaks about the long-term efficacy and safety results from the MonumenTAL-1 trials on talquetamab treatment among patients with MM.

This animation explains the role of BCMA in the life cycle of plasma cells and the effects of overexpression of BCMA on the abnormal survival of these cells.

This animation discusses the role of BCL2 in normal cell function and explains the effects of disruptions in the BCL2 gene on cell signaling.

This animation explains the role of the ALK oncogene in normal cellular functioning and the effect of an abnormal translocation event where ALK fuses to another gene.

This animation explains the role of the 20S proteasome in regulating the cellular life cycle and the effects of disruptions in the ubiquitin proteasome system.

This animation explains the role of the CEACAM5 glycoprotein in the inhibition of cell differentiation and apoptosis, which can promote tumor growth and metastasis.

Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.

Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...